Items Tagged ‘KEYNOTE-028’

December 27th, 2016

Keytruda® Active in Small Cell Lung Cancer


Recently updated findings from the phase 1b KEYNOTE-028 study investigating the use of Keytruda® (pembrolizumab) in small cell lung cancer (SCLC) were recently presented at the 17th World Conference on Lung Cancer. Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, SCLC accounts for 10-20% of all lung cancers. Although progress […]

View full entry

Tags: Extensive Lung Cancer - Small Cell, General Lung Cancer, immunotherapy, KEYNOTE-028, Lung Cancer, Lung Cancer - Small Cell, News, PD-L1 positive, SCLS, small cell lung cancer